Veru Inc. (VERU): Price and Financial Metrics

Veru Inc. (VERU): $0.78

0.02 (-2.88%)

POWR Rating

Component Grades

Momentum

F

Stability

F

Sentiment

Quality

D

VERU Price/Volume Stats

Current price $0.78 52-week high $1.92
Prev. close $0.80 52-week low $0.36
Day low $0.75 Volume 1,836,200
Day high $0.84 Avg. volume 2,287,665
50-day MA $1.23 Dividend yield N/A
200-day MA $0.87 Market Cap 114.18M

VERU Stock Price Chart Interactive Chart >


Veru Inc. (VERU) Company Bio


Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is based in Miami, Florida.


VERU Latest News Stream


Event/Time News Detail
Loading, please wait...

VERU Latest Social Stream


Loading social stream, please wait...

View Full VERU Social Stream

Latest VERU News From Around the Web

Below are the latest news stories about VERU INC that investors may wish to consider to help them evaluate VERU as an investment opportunity.

Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs

MIAMI, FL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress syndrome, today announced it will host an investor conference call and audio webcast on Thursday, January 4, 2024, at 8:00 a.m. ET to discuss the recent financing and the Company’s strategy to prioritize the development of enobosarm for weight loss as well a

Yahoo | December 19, 2023

The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 29%

Veru Inc. ( NASDAQ:VERU ) shares have had a horrible month, losing 29% after a relatively good period beforehand. The...

Yahoo | December 18, 2023

Veru Announces Pricing of Public Offering of Common Stock

MIAMI, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology and viral-induced acute respiratory distress syndrome, announced today the pricing of an underwritten public offering of 45,833,333 shares of its common stock at a price to the public of $0.72 per share. The aggregate gross proceeds to Veru from the offering, before deducting underwriting discoun

Yahoo | December 14, 2023

Veru Announces Proposed Public Offering of Common Stock

MIAMI, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology and viral-induced acute respiratory distress syndrome, announced today that it has commenced an underwritten public offering of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Veru. In addition, Veru intends to grant the underwriters a 30-day o

Yahoo | December 13, 2023

The past year for Veru (NASDAQ:VERU) investors has not been profitable

The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...

Yahoo | November 10, 2023

Read More 'VERU' Stories Here

VERU Price Returns

1-mo -43.07%
3-mo 39.29%
6-mo 9.86%
1-year -33.33%
3-year -90.83%
5-year -63.55%
YTD 8.33%
2023 -86.36%
2022 -10.36%
2021 -31.91%
2020 158.21%
2019 139.29%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!